糖尿病前期
医学
糖耐量受损
糖尿病
空腹血糖受损
血糖性
2型糖尿病
内科学
血糖调节
胰岛素抵抗
果糖胺
糖耐量试验
葡萄糖稳态
内分泌学
生物信息学
生物
作者
Michael Bergman,Muhammad Abdul‐Ghani,Ralph A. DeFronzo,Melania Manco,Giorgio Sesti,Teresa Vanessa Fiorentino,Antonio Ceriello,Mary K. Rhee,Lawrence S. Phillips,Stephanie T. Chung,CELESTE K. CRAVALHO,Ram Jagannathan,Louis Monnier,C Colette,David R. Owens,Cristina Bianchi,Stefano Del Prato,Mariana P. Monteiro,João Sérgio Neves,José Luís Medina
标识
DOI:10.1016/j.diabres.2020.108233
摘要
Prediabetes (intermediate hyperglycemia) consists of two abnormalities, impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) detected by a standardized 75-gram oral glucose tolerance test (OGTT). Individuals with isolated IGT or combined IFG and IGT have increased risk for developing type 2 diabetes (T2D) and cardiovascular disease (CVD). Diagnosing prediabetes early and accurately is critical in order to refer high-risk individuals for intensive lifestyle modification. However, there is currently no international consensus for diagnosing prediabetes with HbA1c or glucose measurements based upon American Diabetes Association (ADA) and the World Health Organization (WHO) criteria that identify different populations at risk for progressing to diabetes. Various caveats affecting the accuracy of interpreting the HbA1c including genetics complicate this further. This review describes established methods for detecting glucose disorders based upon glucose and HbA1c parameters as well as novel approaches including the 1-hour plasma glucose (1-h PG), glucose challenge test (GCT), shape of the glucose curve, genetics, continuous glucose monitoring (CGM), measures of insulin secretion and sensitivity, metabolomics, and ancillary tools such as fructosamine, glycated albumin (GA), 1,5- anhydroglucitol (1,5-AG). Of the approaches considered, the 1-h PG has considerable potential as a biomarker for detecting glucose disorders if confirmed by additional data including health economic analysis. Whether the 1-h OGTT is superior to genetics and omics in providing greater precision for individualized treatment requires further investigation. These methods will need to demonstrate substantially superiority to simpler tools for detecting glucose disorders to justify their cost and complexity.
科研通智能强力驱动
Strongly Powered by AbleSci AI